Interim analysis from the APPLAUSE-IgAN trial found favorable results for the use of iptacopan in IgAN.
A super-learner strategy gave accurate risk predictions of kidney failure and death for people with moderate to severe CKD.
Longer follow-up results of the RUBY-3 trial found povetacicept is well-tolerated and shows promise for IgAN treatment.
Researchers uncovered clinical and economic of the Kidney BEAM physical activity digital health intervention for CKD.
Researchers found that sparsentan had a clinically meaningful benefit on long-term kidney preservation versus irbesartan.
Researchers studied the prevalence of hyperkalemia in patients at a facility in Durban, South Africa.
Researchers reported on real-world use of SZC for hyperkalemia in a cohort of Asian hemodialysis patients.
A simulation model predicts a dramatic increase in the impact of chronic kidney disease in the next 10 years.
Advertisement
Advertisement
